1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
Breast Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030

Breast Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030

  • April 2021
  • 175 pages
  • ID: 6067908
  • Format: PDF
  • The Business Research Company

Summary

Table of Contents

Major players in the breast cancer drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca, Eli Lilly and Company, and Celgene Corporation.

The global breast cancer drugs market is expected to grow from $14.25 billion in 2020 to $14.82 billion in 2021 at a compound annual growth rate (CAGR) of 4%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $19.49 billion in 2025 at a CAGR of 7.1%.

The breast cancer drugs market consists of sales of breast cancer drugs and related services. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapy for treating breast cancer.

Manufacturers of breast cancer drugs are governed by various regulatory bodies such as the Food and Drug Administration in the USA and the European Medicines Agency in the European Union.The European medicinces agency (EMA) regulates the market for breast cancer drugs by granting licences to the drugs that have been proven to be safe and clinically effective.

The drug is evaluated to understand its benefits and risks and then tested for any post usage effects.The drug can be commercially sold in the European Union upon approval from the EMA.

The EMA can also grant a “conditional marketing authorisation"" indicating approval, but can withdraw it if found unsafe or ineffective.

Manufacturers of breast cancer drugs are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge and expand business. For instance, in March 2019, Astrazeneca entered into a partnership deal worth $6.9 billion for the development of a breast cancer drug. According to the deal, the companies will jointly develop the drug trastuzumab deruxtecan and will share development and commercialization costs for the drug worldwide. Novartis collaborated with IBM Watson Health for the development of a solution that can determine drug combinations and sequences for best patient outcomes.

The increasing prevalence of breast cancer is driving the breast cancer drugs market. Breast cancer is the most common type of cancer among women and affects around 2.1 million women each year. According to the World Health Organization, in 2018, an estimated 627,000 women died from breast cancer, accounting for 15% of all cancer related deaths among women. The factors responsible for breast cancer include heredity, age, lifestyle of a person and is more common in developed countries. As the number of people diagnosed with breast cancer rises, the demand for breast cancer drugs increases, thereby driving market growth.

Adverse side effects caused by the use of breast cancer drugs is acting as a restraint on the breast cancer drugs market.Breast cancer drugs can result in long term or short term side effects including headaches, dental issues, osteoporosis, heart problems, cataracts, blood clots, infertility and others.

As a result, patients depend on alternate or complementary treatments to deal with the side effects, thereby increasing overall treatment costs. Also, the long lasting nature of some of the side effects discourage the use of breast cancer drugs, affecting market growth.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on